Company intelligence / Profile preview
Molecular Targeting Technologies, Inc.
West Chester, Pennsylvania, United Statesmtarget.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
The company has developed multiple diagnostic and therapeutic molecules, including 18F-Fluoroglucaric acid (FGA) for imaging necrosis, and is advancing its EvaThera platform for targeted radiotherapeutics. They expected to orchestrate multiple clinical trials in 2021.
- Therapeutic areas
- GastroenterologyCardiovascularNephrologyOncologyNeurologyInfectious Diseases
- Modalities
- RadiotherapeuticsRadiodiagnosticsPeptide Receptor Radionuclide Therapy (PRRT)Imaging agents
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
Request access →03
Partnerships
NIH
Beyond the preview
Go deeper on Molecular Targeting Technologies, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Molecular Targeting Technologies, Inc..